Axa
TVTX icon

Axa’s Travere Therapeutics TVTX Stock Holding History

Axa’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,200
Closed -$118K – 1135
2023
Q3 		$118K Sell
13,200
-40,400
-75% -$570K ﹤0.01% 1039
2023
Q2 		$823K Sell
53,600
-299,187
-85% -$5.44M ﹤0.01% 868
2023
Q1 		$7.93M Buy
352,787
+81,575
+30% +$1.73M 0.03% 461
2022
Q4 		$5.7M Sell
271,212
-5,285
-2% -$112K 0.02% 559
2022
Q3 		$6.81M Buy
276,497
+46,407
+20% +$1.2M 0.03% 516
2022
Q2 		$5.58M Buy
230,090
+48,457
+27% +$1.22M 0.02% 553
2022
Q1 		$4.68M Buy
181,633
+160,233
+749% +$4.25M 0.01% 657
2021
Q4 		$664K Buy
+21,400
New +$603K ﹤0.01% 995
2021
Q3 		– Sell
-143,900
Closed -$2.1M – 1323
2021
Q2 		$2.1M Sell
143,900
-179,818
-56% -$3.55M 0.01% 879
2021
Q1 		$8.08M Buy
323,718
+133,518
+70% +$3.69M 0.02% 566
2020
Q4 		$5.18M Hold
190,200
– – 0.02% 686
2020
Q3 		$3.51M Hold
190,200
– – 0.01% 717
2020
Q2 		$3.88M Sell
190,200
-7,200
-4% -$115K 0.02% 686
2020
Q1 		$2.88M Buy
197,400
+32,000
+19% +$481K 0.01% 659
2019
Q4 		$2.35M Hold
165,400
– – 0.01% 779
2019
Q3 		$1.92M Buy
+165,400
New +$2.73M 0.01% 870
2016
Q1 		– Sell
-46,400
Closed -$895K – 1418
2015
Q4 		$895K Buy
46,400
+43,300
+1,397% +$865K ﹤0.01% 936
2015
Q3 		$63K Buy
+3,100
New +$91.8K ﹤0.01% 1340

Other funds holding TVTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Axa's TVTX Position: Q4 2023 in Review

Axa sold out of Travere Therapeutics (TVTX) in Q4 2023, closing a stake of 13,200 shares — an estimated $118K sold.

Axa first reported a position in TVTX in Q3 2015 and held it in 18 quarters. The position peaked at $8.08M in Q1 2021. 165 funds tracked by Wall St. Rank hold TVTX as of Q4 2023.

  • Axa reported no remaining Travere Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Axa sold 13,200 Travere Therapeutics shares in Q4 2023, an estimated $118K.
  • Axa first reported a position in Travere Therapeutics in Q3 2015 and held it in 18 quarters.
  • Axa's Travere Therapeutics position peaked at $8.08M in Q1 2021.
  • 165 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2023.

Based on Axa's 13F filing for Q4 2023, filed 14 Feb 2024.